查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1585818

液態切片測試設備市場：按報價、循環生物標記、最終用戶、應用 - 2025-2030 年全球預測

Breast Cancer Liquid Biopsy Testing Devices Market by Offerings (Assay & Reagents Kits, Instruments), Circulating Biomarker (Circulating Tumar DNA, Circulating Tumor Cell, Extracellular Vesicles), End-User, Appplication - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 193 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

乳癌液態切片檢測設備市場2023年價值8.5876億美元，預計2024年將達到10.236億美元，複合年成長率為19.59%，到2030年將達30.0457億美元。

乳癌液態切片檢測設備的範圍和定義包括旨在檢測血液中循環的腫瘤細胞和DNA的診斷工具，為傳統切片檢查提供非侵入性替代方案。這些設備對於癌症的早期檢測、監測疾病進展和個人化治療計劃至關重要，這使得它們對於精準醫療至關重要。應用範圍包括臨床診斷、治療監測和預後預測，最終用途為醫院、診斷實驗室和研究機構。推動乳癌液態切片市場的主要成長要素包括癌症發生率的增加、對非侵入性手術的需求增加以及分子​​生物學技術的進步。最近的潛在商機在於人工智慧和機器學習的整合，以提高資料分析的準確性，以及擴大早期檢測和即時監控的應用，特別是在醫療基礎設施正在發展的發展中地區。然而，該市場面臨一些限制，例如先進測試的高成本、監管障礙以及醫生和患者意識有限。解決測試敏感性和特異性方面的挑戰對於更廣泛的採用仍然至關重要。創新的最佳領域包括改善生物標記發現、降低營運成本以及利用次世代定序和其他基因組技術增強測試預測能力。對乳癌異質性及其複雜生物學的研究可能會進一步最佳化這些檢測儀器的有效性。市場本質上是動態的，技術發展迅速，傳統切片檢查方法面臨競爭壓力。為了保持競爭力，公司應專注於合作研究夥伴關係關係，利用巨量資料進行個人化醫療，並增加研發投資。利用新的商機需要加強教育、監管推廣和策略聯盟，以幫助駕馭複雜的醫療保健系統，並有效地將具有成本效益的解決方案推向市場。

主要市場統計
基準年[2023] 85876萬美元
預測年份 [2024] 10.236 億美元
預測年份 [2030] 3,004,570,000 美元
複合年成長率（%） 19.59%

市場動態：快速發展的乳癌液態切片測試設備市場的關鍵市場洞察

液態切片檢測設備市場正在因供需的動態交互作用而轉變。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，並了解消費行為及其對製造成本的影響，並更清楚地了解對採購趨勢的影響。

  • 市場促進因素
    • 世界各地女性乳癌發生率不斷上升
    • 對非侵入性乳癌治療的需求不斷成長
    • 乳癌預篩檢計畫的激增
  • 市場限制因素
    • 對檢測設備準確性的擔憂
  • 市場機會
    • 液態切片檢測設備的技術進展
    • 乳癌檢測的研發投資
  • 市場挑戰
    • 液態切片有嚴格的標準

波特五力：開拓液態切片測試設備市場的策略工具

波特的五力框架是理解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解液態切片檢測設備市場的外部影響

外部宏觀環境因素在塑造液態切片測試設備市場的績效動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析 了解液態切片檢測設備市場競爭格局

對液態切片測試設備市場的詳細市場佔有率分析可以對供應商的績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，以應對日益激烈的競爭。

FPNV定位矩陣乳癌液態切片測試設備市場供應商的績效評估

FPNV 定位矩陣是評估液態切片測試設備市場供應商的重要工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，以確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析和建議，描繪乳癌液態切片測試設備市場的成功之路

對於旨在加強其在全球市場的影響力的公司來說，對液態切片測試設備市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機，並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：對當前市場環境的詳細審查、主要企業的廣泛資料、對其在市場中的影響力和整體影響力的評估。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點關注可望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 全球女性乳癌發生率正在上升
      • 對非侵入性乳癌治療的需求增加
      • 乳癌預篩檢計畫的激增
    • 抑制因素
      • 對檢測設備準確性的擔憂
    • 機會
      • 液態切片檢測設備的技術進展
      • 乳癌檢測研發投資
    • 任務
      • 液態生物檢體有嚴格的標準
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章液態切片檢測設備市場：透過提供

  • 測定和試劑組
  • 裝置

第7章液態切片檢測設備市場：透過循環生物標記

  • 循環腫瘤DNA
  • 循環性腫瘤細胞
  • 細胞外囊泡

第8章液態切片測試設備市場：依最終用戶分類

  • 醫院
  • 研究室

第9章液態切片檢測設備市場：依應用分類

  • 診斷
  • 監視
  • 篩檢/早期發現
  • 治療選擇

第10章 北美和南美液態切片檢測設備市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第11章亞太地區液態切片檢測設備市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第12章歐洲、中東和非洲液態切片檢測設備市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第13章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • Agilent Technologies, Inc.
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • Biocept, Inc.
  • Biodesix, Inc.
  • BioVIew Ltd.
  • Eurofins Scientific SE
  • Exact Sciences Corporation
  • F. Hoffmann-La Roche AG
  • Fluxion Biosciences Inc.
  • Guardant Health, Inc.
  • Illumina, Inc.
  • Isogen Life Science BV
  • Johnson & Johnson Services, Inc.
  • Laboratory Corporation of America Holdings
  • Lucence Health Inc.
  • Menarini Group
  • Merck KGaA
  • Myriad Genetics, Inc.
  • Natera Inc.
  • Neogenomics Laboratories, Inc.
  • OncoDNA SA
  • Qiagen NV
  • Sysmex Corporation
  • Thermo Fisher Scientific Inc.
Product Code: MRR-742BD517C0D8

The Breast Cancer Liquid Biopsy Testing Devices Market was valued at USD 858.76 million in 2023, expected to reach USD 1,023.60 million in 2024, and is projected to grow at a CAGR of 19.59%, to USD 3,004.57 million by 2030.

The scope and definition of breast cancer liquid biopsy testing devices encompass diagnostic tools designed to detect cancer cells or DNA from tumors circulating in the blood, offering a non-invasive alternative to traditional biopsies. These devices are crucial for early cancer detection, monitoring disease progression, and personalizing treatment plans, making them indispensable in precision medicine. The application scope spans clinical diagnostics, treatment monitoring, and prognosis, with end-use sectors including hospitals, diagnostic laboratories, and research institutions. Key growth factors driving the breast cancer liquid biopsy market include increasing cancer prevalence, rising demand for non-invasive procedures, and advancements in molecular biology technology. Recent potential opportunities lie in the integration of artificial intelligence and machine learning to enhance data analysis accuracy, as well as expanding applications in early-stage detection and real-time monitoring, particularly in developing regions with growing healthcare infrastructure. However, the market faces limitations such as high costs of advanced testing, regulatory hurdles, and limited awareness among practitioners and patients. Addressing challenges around sensitivity and specificity of tests remains crucial for broader adoption. Best areas for innovation include improving biomarker discovery, reducing operational costs, and enhancing the test's predictive capabilities through next-generation sequencing and other genomic technologies. Research into the heterogeneity of breast cancer and its complex biology may further optimize the efficacy of these devices. The market is inherently dynamic, with rapid technological evolution and competitive pressures from traditional biopsy methods. Companies should focus on collaborative research partnerships, leveraging big data for personalized medicine, and increased investment in R&D to maintain a competitive edge. To capitalize on emerging opportunities, there is a need for increasing educational efforts, regulatory advocacy, and strategic alliances that can help navigate complex healthcare systems and bring cost-effective solutions to market efficiently.

KEY MARKET STATISTICS
Base Year [2023] USD 858.76 million
Estimated Year [2024] USD 1,023.60 million
Forecast Year [2030] USD 3,004.57 million
CAGR (%) 19.59%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Breast Cancer Liquid Biopsy Testing Devices Market

The Breast Cancer Liquid Biopsy Testing Devices Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising prevalence of breast cancer among women worldwide
    • Increasing demand for non-invasive breast cancer treatment
    • Surge in pre-screening programs for breast cancer detection
  • Market Restraints
    • Concerns related to the accuracy of testing devices
  • Market Opportunities
    • Technological advancements in breast cancer liquid biopsy testing devices
    • Investments in R&D for breast cancer testing
  • Market Challenges
    • Presence of strict standards for liquid biopsy

Porter's Five Forces: A Strategic Tool for Navigating the Breast Cancer Liquid Biopsy Testing Devices Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Breast Cancer Liquid Biopsy Testing Devices Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Breast Cancer Liquid Biopsy Testing Devices Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Breast Cancer Liquid Biopsy Testing Devices Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Breast Cancer Liquid Biopsy Testing Devices Market

A detailed market share analysis in the Breast Cancer Liquid Biopsy Testing Devices Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Breast Cancer Liquid Biopsy Testing Devices Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Breast Cancer Liquid Biopsy Testing Devices Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Breast Cancer Liquid Biopsy Testing Devices Market

A strategic analysis of the Breast Cancer Liquid Biopsy Testing Devices Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Breast Cancer Liquid Biopsy Testing Devices Market, highlighting leading vendors and their innovative profiles. These include Agilent Technologies, Inc., Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., Biocept, Inc., Biodesix, Inc., BioVIew Ltd., Eurofins Scientific SE, Exact Sciences Corporation, F. Hoffmann-La Roche AG, Fluxion Biosciences Inc., Guardant Health, Inc., Illumina, Inc., Isogen Life Science B.V., Johnson & Johnson Services, Inc., Laboratory Corporation of America Holdings, Lucence Health Inc., Menarini Group, Merck KGaA, Myriad Genetics, Inc., Natera Inc., Neogenomics Laboratories, Inc., OncoDNA SA, Qiagen N.V., Sysmex Corporation, and Thermo Fisher Scientific Inc..

Market Segmentation & Coverage

This research report categorizes the Breast Cancer Liquid Biopsy Testing Devices Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Offerings, market is studied across Assay & Reagents Kits and Instruments.
  • Based on Circulating Biomarker, market is studied across Circulating Tumar DNA, Circulating Tumor Cell, and Extracellular Vesicles.
  • Based on End-User, market is studied across Hospitals and Research Laboratories.
  • Based on Appplication, market is studied across Diagnosis, Monitoring, Screening/Early Detection, and Treatment Selection.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising prevalence of breast cancer among women worldwide
      • 5.1.1.2. Increasing demand for non-invasive breast cancer treatment
      • 5.1.1.3. Surge in pre-screening programs for breast cancer detection
    • 5.1.2. Restraints
      • 5.1.2.1. Concerns related to the accuracy of testing devices
    • 5.1.3. Opportunities
      • 5.1.3.1. Technological advancements in breast cancer liquid biopsy testing devices
      • 5.1.3.2. Investments in R&D for breast cancer testing
    • 5.1.4. Challenges
      • 5.1.4.1. Presence of strict standards for liquid biopsy
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Breast Cancer Liquid Biopsy Testing Devices Market, by Offerings

  • 6.1. Introduction
  • 6.2. Assay & Reagents Kits
  • 6.3. Instruments

7. Breast Cancer Liquid Biopsy Testing Devices Market, by Circulating Biomarker

  • 7.1. Introduction
  • 7.2. Circulating Tumar DNA
  • 7.3. Circulating Tumor Cell
  • 7.4. Extracellular Vesicles

8. Breast Cancer Liquid Biopsy Testing Devices Market, by End-User

  • 8.1. Introduction
  • 8.2. Hospitals
  • 8.3. Research Laboratories

9. Breast Cancer Liquid Biopsy Testing Devices Market, by Appplication

  • 9.1. Introduction
  • 9.2. Diagnosis
  • 9.3. Monitoring
  • 9.4. Screening/Early Detection
  • 9.5. Treatment Selection

10. Americas Breast Cancer Liquid Biopsy Testing Devices Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Breast Cancer Liquid Biopsy Testing Devices Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Breast Cancer Liquid Biopsy Testing Devices Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Agilent Technologies, Inc.
  • 2. Becton, Dickinson and Company
  • 3. Bio-Rad Laboratories, Inc.
  • 4. Biocept, Inc.
  • 5. Biodesix, Inc.
  • 6. BioVIew Ltd.
  • 7. Eurofins Scientific SE
  • 8. Exact Sciences Corporation
  • 9. F. Hoffmann-La Roche AG
  • 10. Fluxion Biosciences Inc.
  • 11. Guardant Health, Inc.
  • 12. Illumina, Inc.
  • 13. Isogen Life Science B.V.
  • 14. Johnson & Johnson Services, Inc.
  • 15. Laboratory Corporation of America Holdings
  • 16. Lucence Health Inc.
  • 17. Menarini Group
  • 18. Merck KGaA
  • 19. Myriad Genetics, Inc.
  • 20. Natera Inc.
  • 21. Neogenomics Laboratories, Inc.
  • 22. OncoDNA SA
  • 23. Qiagen N.V.
  • 24. Sysmex Corporation
  • 25. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET RESEARCH PROCESS
  • FIGURE 2. BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY OFFERINGS, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY OFFERINGS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY CIRCULATING BIOMARKER, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY CIRCULATING BIOMARKER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY APPPLICATION, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY APPPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET DYNAMICS
  • TABLE 7. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY ASSAY & REAGENTS KITS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY CIRCULATING BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY CIRCULATING TUMAR DNA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY CIRCULATING TUMOR CELL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY EXTRACELLULAR VESICLES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY RESEARCH LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY APPPLICATION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY DIAGNOSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY MONITORING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY SCREENING/EARLY DETECTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY TREATMENT SELECTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY CIRCULATING BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY APPPLICATION, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 27. ARGENTINA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
  • TABLE 28. ARGENTINA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY CIRCULATING BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 29. ARGENTINA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 30. ARGENTINA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY APPPLICATION, 2018-2030 (USD MILLION)
  • TABLE 31. BRAZIL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
  • TABLE 32. BRAZIL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY CIRCULATING BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 33. BRAZIL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 34. BRAZIL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY APPPLICATION, 2018-2030 (USD MILLION)
  • TABLE 35. CANADA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
  • TABLE 36. CANADA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY CIRCULATING BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 37. CANADA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 38. CANADA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY APPPLICATION, 2018-2030 (USD MILLION)
  • TABLE 39. MEXICO BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
  • TABLE 40. MEXICO BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY CIRCULATING BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 41. MEXICO BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 42. MEXICO BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY APPPLICATION, 2018-2030 (USD MILLION)
  • TABLE 43. UNITED STATES BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
  • TABLE 44. UNITED STATES BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY CIRCULATING BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 45. UNITED STATES BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 46. UNITED STATES BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY APPPLICATION, 2018-2030 (USD MILLION)
  • TABLE 47. UNITED STATES BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 48. ASIA-PACIFIC BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
  • TABLE 49. ASIA-PACIFIC BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY CIRCULATING BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 50. ASIA-PACIFIC BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 51. ASIA-PACIFIC BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY APPPLICATION, 2018-2030 (USD MILLION)
  • TABLE 52. ASIA-PACIFIC BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 53. AUSTRALIA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
  • TABLE 54. AUSTRALIA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY CIRCULATING BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 55. AUSTRALIA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 56. AUSTRALIA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY APPPLICATION, 2018-2030 (USD MILLION)
  • TABLE 57. CHINA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
  • TABLE 58. CHINA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY CIRCULATING BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 59. CHINA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 60. CHINA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY APPPLICATION, 2018-2030 (USD MILLION)
  • TABLE 61. INDIA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
  • TABLE 62. INDIA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY CIRCULATING BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 63. INDIA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 64. INDIA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY APPPLICATION, 2018-2030 (USD MILLION)
  • TABLE 65. INDONESIA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
  • TABLE 66. INDONESIA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY CIRCULATING BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 67. INDONESIA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 68. INDONESIA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY APPPLICATION, 2018-2030 (USD MILLION)
  • TABLE 69. JAPAN BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
  • TABLE 70. JAPAN BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY CIRCULATING BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 71. JAPAN BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 72. JAPAN BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY APPPLICATION, 2018-2030 (USD MILLION)
  • TABLE 73. MALAYSIA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
  • TABLE 74. MALAYSIA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY CIRCULATING BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 75. MALAYSIA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 76. MALAYSIA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY APPPLICATION, 2018-2030 (USD MILLION)
  • TABLE 77. PHILIPPINES BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
  • TABLE 78. PHILIPPINES BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY CIRCULATING BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 79. PHILIPPINES BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 80. PHILIPPINES BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY APPPLICATION, 2018-2030 (USD MILLION)
  • TABLE 81. SINGAPORE BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
  • TABLE 82. SINGAPORE BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY CIRCULATING BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 83. SINGAPORE BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 84. SINGAPORE BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY APPPLICATION, 2018-2030 (USD MILLION)
  • TABLE 85. SOUTH KOREA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
  • TABLE 86. SOUTH KOREA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY CIRCULATING BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 87. SOUTH KOREA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 88. SOUTH KOREA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY APPPLICATION, 2018-2030 (USD MILLION)
  • TABLE 89. TAIWAN BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
  • TABLE 90. TAIWAN BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY CIRCULATING BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 91. TAIWAN BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 92. TAIWAN BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY APPPLICATION, 2018-2030 (USD MILLION)
  • TABLE 93. THAILAND BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
  • TABLE 94. THAILAND BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY CIRCULATING BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 95. THAILAND BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 96. THAILAND BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY APPPLICATION, 2018-2030 (USD MILLION)
  • TABLE 97. VIETNAM BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
  • TABLE 98. VIETNAM BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY CIRCULATING BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 99. VIETNAM BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 100. VIETNAM BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY APPPLICATION, 2018-2030 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY CIRCULATING BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY APPPLICATION, 2018-2030 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 106. DENMARK BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
  • TABLE 107. DENMARK BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY CIRCULATING BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 108. DENMARK BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 109. DENMARK BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY APPPLICATION, 2018-2030 (USD MILLION)
  • TABLE 110. EGYPT BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
  • TABLE 111. EGYPT BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY CIRCULATING BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 112. EGYPT BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 113. EGYPT BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY APPPLICATION, 2018-2030 (USD MILLION)
  • TABLE 114. FINLAND BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
  • TABLE 115. FINLAND BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY CIRCULATING BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 116. FINLAND BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 117. FINLAND BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY APPPLICATION, 2018-2030 (USD MILLION)
  • TABLE 118. FRANCE BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
  • TABLE 119. FRANCE BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY CIRCULATING BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 120. FRANCE BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 121. FRANCE BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY APPPLICATION, 2018-2030 (USD MILLION)
  • TABLE 122. GERMANY BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
  • TABLE 123. GERMANY BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY CIRCULATING BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 124. GERMANY BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 125. GERMANY BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY APPPLICATION, 2018-2030 (USD MILLION)
  • TABLE 126. ISRAEL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
  • TABLE 127. ISRAEL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY CIRCULATING BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 128. ISRAEL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 129. ISRAEL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY APPPLICATION, 2018-2030 (USD MILLION)
  • TABLE 130. ITALY BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
  • TABLE 131. ITALY BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY CIRCULATING BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 132. ITALY BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 133. ITALY BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY APPPLICATION, 2018-2030 (USD MILLION)
  • TABLE 134. NETHERLANDS BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
  • TABLE 135. NETHERLANDS BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY CIRCULATING BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 136. NETHERLANDS BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 137. NETHERLANDS BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY APPPLICATION, 2018-2030 (USD MILLION)
  • TABLE 138. NIGERIA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
  • TABLE 139. NIGERIA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY CIRCULATING BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 140. NIGERIA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 141. NIGERIA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY APPPLICATION, 2018-2030 (USD MILLION)
  • TABLE 142. NORWAY BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
  • TABLE 143. NORWAY BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY CIRCULATING BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 144. NORWAY BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 145. NORWAY BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY APPPLICATION, 2018-2030 (USD MILLION)
  • TABLE 146. POLAND BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
  • TABLE 147. POLAND BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY CIRCULATING BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 148. POLAND BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 149. POLAND BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY APPPLICATION, 2018-2030 (USD MILLION)
  • TABLE 150. QATAR BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
  • TABLE 151. QATAR BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY CIRCULATING BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 152. QATAR BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 153. QATAR BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY APPPLICATION, 2018-2030 (USD MILLION)
  • TABLE 154. RUSSIA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
  • TABLE 155. RUSSIA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY CIRCULATING BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 156. RUSSIA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 157. RUSSIA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY APPPLICATION, 2018-2030 (USD MILLION)
  • TABLE 158. SAUDI ARABIA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
  • TABLE 159. SAUDI ARABIA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY CIRCULATING BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 160. SAUDI ARABIA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 161. SAUDI ARABIA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY APPPLICATION, 2018-2030 (USD MILLION)
  • TABLE 162. SOUTH AFRICA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
  • TABLE 163. SOUTH AFRICA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY CIRCULATING BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 164. SOUTH AFRICA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 165. SOUTH AFRICA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY APPPLICATION, 2018-2030 (USD MILLION)
  • TABLE 166. SPAIN BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
  • TABLE 167. SPAIN BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY CIRCULATING BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 168. SPAIN BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 169. SPAIN BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY APPPLICATION, 2018-2030 (USD MILLION)
  • TABLE 170. SWEDEN BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
  • TABLE 171. SWEDEN BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY CIRCULATING BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 172. SWEDEN BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 173. SWEDEN BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY APPPLICATION, 2018-2030 (USD MILLION)
  • TABLE 174. SWITZERLAND BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
  • TABLE 175. SWITZERLAND BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY CIRCULATING BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 176. SWITZERLAND BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 177. SWITZERLAND BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY APPPLICATION, 2018-2030 (USD MILLION)
  • TABLE 178. TURKEY BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
  • TABLE 179. TURKEY BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY CIRCULATING BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 180. TURKEY BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 181. TURKEY BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY APPPLICATION, 2018-2030 (USD MILLION)
  • TABLE 182. UNITED ARAB EMIRATES BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
  • TABLE 183. UNITED ARAB EMIRATES BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY CIRCULATING BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 184. UNITED ARAB EMIRATES BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED ARAB EMIRATES BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY APPPLICATION, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED KINGDOM BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED KINGDOM BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY CIRCULATING BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED KINGDOM BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED KINGDOM BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY APPPLICATION, 2018-2030 (USD MILLION)
  • TABLE 190. BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 191. BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET, FPNV POSITIONING MATRIX, 2023